COMP <GO>
SRPT vs MRVI // OPERATING MARGIN
Sarepta Therapeutics Inc. (NASDAQ) VS. Maravai LifeSciences Holdings Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: SRPT 7
— MRVI 2
▲ OPERATING MARGIN LEADER: SRPT
LAST: $18.32 (-1.61%) • MKT CAP: $1.94B
operating-margins
-37.50%
LAST: $7.19 (-7.94%) • MKT CAP: $1.87B
operating-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SRPT VS. MRVI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SRPT | MRVI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 18.30% | +77.70 | SRPT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -15.14% | -3.22% | -11.92 | MRVI | /fcf-yield <GO> |
| Operating Margin ACTIVE | -37.50% | -60.00% | +22.50 | SRPT | /operating-margins <GO> |
| Net Profit Margin | -38.30% | -60.00% | +21.70 | SRPT | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | -28.30% | +32.60 | SRPT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 3.04 | -2.84 | MRVI | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 3/9 | +1.00 | SRPT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.7 | 46.2 | +2.50 | SRPT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.94B | $1.87B | $68.0M | SRPT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SRPT REV | MRVI REV | SRPT GROSS % | MRVI GROSS % | SRPT FCF | MRVI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.86B | $185.7M | 98.0% | 18.3% | -$307.5M | -$70.7M |
| FY 2024 | $1.79B | $259.2M | — | 41.8% | -$342.7M | -$22.2M |
| FY 2023 | $1.14B | $288.9M | — | — | -$501.0M | $126.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SRPT // BETA —
MRVI // BETA —